8-K - Calidi Biotherapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Calidi Biotherapeutics Board of Directors to shrink from six to five members upon expiration of Allan J. Camaisa's term at the 2026 annual stockholder meeting, with no disagreements cited.

Key Takeaways

1Mr. Allan J. Camaisa intends to allow his director term to expire at the 2026 annual stockholder meeting.

2Camaisa's decision resulted from no disagreement with Company operations, policies or practices.

3Board reduced size from six to five directors effective on 2026 annual stockholder meeting date.

4Board eliminated Class III director vacancy following Camaisa's notice.

5Scott Leftwich appointed to Audit Committee effective April 1, 2026.

Current Report Details

Event Type

Management Change

Other Event

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

above is also incorporated herein by reference. ** ** **Item 9.01 Financial Statements and Exhibits.** (d) Exhibits | Exhibit | | Exhibit Description | |---|

Management Change

8.01

Other Events.** ** ** On April 1, 2026, following the receipt of notice from Mr. Camaisa, and as permitted by the Bylaws of the Company, the Board at the recomm

Other Event

Executive & Director Changes

Allan J. Camaisa

Director (Class III)

Term to expire

Effective: Date of 2026 annual stockholder meeting

Intends to allow term to expire; no disagreement with Company

Scott Leftwich

Class III director

Appointed to Audit Committee

Effective: April 1, 2026

Recommendation of Nominating and Corporate Governance Committee

Exhibits (1)

8-K